Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 8/20 | 0.73 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.73 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 7/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7798340 | 0.84 | PTGER3 (1.00) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL7798336 | 0.84 | PTGER3 (1.00) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL2574855 | 0.83 | PTGER4 (0.55) | PTGER4PTGER3PTGER2PTGER1HTR1A | |
| SCHEMBL7961865 | 0.82 | PTGER4 (0.69) | PTGER4PTGER3PTGER2PTGER1BCHE | |
| SCHEMBL7947922 | 0.82 | PTGER3 (0.82) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL7961856 | 0.81 | PTGER3 (0.80) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL7961860 | 0.81 | PTGER3 (0.80) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL7807171 | 0.80 | PTGER4 (0.73) | PTGER4PTGER3PTGER2PTGER1ALDH1A1 | |
| SCHEMBL7955267 | 0.80 | PTGER4 (1.00) | PTGER4PTGER3PTGER2PTGER1 | |
| SCHEMBL1539474 | 0.79 | CDK4 (0.50) | PTGER4PTGER3PTGER2PTGER1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | MERCK FROSST CANADA & CO. | 2001-10-18 | — | — | US | disclosed |
| EP-1119542-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2001-08-01 | — | — | EP | disclosed |
| US-6211197-B1 | CARBOXYLIC ACID OR TETRAZOLE DERIVATES; ANALGESICS, ANTIPYRETICS, AND ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2001-04-03 | — | — | US | disclosed |
| WO-2000020371-A1 | PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031766-A1 | Prostaglandin receptor ligands | PTGER1, PTGER2, PTGFR | PTGER4 11/4885PTGER3 9/4885PTGER2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.